New treatments for advanced non-small cell lung cancer

Increasing the chance to live longer

non-small cell lung cancer

The FDA has approved Opdivo® (Nivolumab) and Keytruda® (Pembrolizumab) to treat patients with advanced non-small cell lung cancer. Both medicines stimulate a patient’s own immune system to destroy cancer cells.

 

Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses in 2014. The most common type of lung cancer, non-small cell lung cancer or NSCLC, affects seven out of eight lung cancer patients.

In October 2015, the U.S. Food and Drug Administration approved Opdivo® (Nivolumab) and Keytruda® (Pembrolizumab) to treat patients with advanced, or metastatic, NSCLC. Both medicines stimulate a patient’s own immune system to destroy cancer cells.

At the University of Michigan’s Multidisciplinary Lung Cancer Clinic, we are using both drugs in appropriate patients as standard of care. We also have other similar immunotherapy drugs in a variety of clinical trials.

Continue reading